PULMONARY MANIFESTATIONS OF SYSTEMIC VASCULITIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is devoted to the evaluation and analysis of modern ideas about the etiology, diagnosis and treatment of systemic vasculitis. An evaluation of studies on the efficacy and safety of drugs prescribed in the treatment of systemic vasculitis has been conducted. The statistical data of the European Vasculitis Study Group are presented. There is a need for continuous monitoring of the course of the disease, which minimizes the risk of complications and death associated with both the disease and complications of therapy.

Full Text

Restricted Access

About the authors

SA. A Terpigorev

SBHCI MR MRSRCI n.a. M.F. Vladimirsky

Email: smith42@yandex.ru
MD, Head of the Department of Occupational Pathology and MLEE

A. M Nikishenkov

SBHCI MR MRSRCI n.a. M.F. Vladimirsky

References

  1. Firikielman J.D., Use A.S., Hummel A.M., et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am. J. Med. 2007;120(7):643.
  2. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Flores-Suarez LF, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.
  3. Bielsa I. Actualización en la nomenclatura de las vasculitis. ConferenciadeConsenso Inter- nacional de Chapel Hill, 2012. Actas Dermosifiliogr. 2015;106(lssue 8):605-8.
  4. Allenbach Y., Seror R., Pagnoux C., et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann. Rheum. Dis. 2009;68(4):564-67.
  5. Flossmann O., Berden A., de Groot K., et al. Ьпд-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 2011; 70(3):488-94.
  6. Frankel S.K., Sullivan E.J., Brown K.K. Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa and Takayasu arteritis. Crit Care Clinics. 2002.18:855-79.
  7. Lane S.E., Watts R., Scott D.G. Epidemiology of systemic vasculitis. Curr. Rheumatol. Rep. 2005;7(4):270-75.
  8. Damoiseaux J., Csernok E., Rasmussen N., Cohen Tervaert J. W., Bossuyt X. Antineutrophil cytoplasmic antibodies: reporting and diagnostic strategies. Ann Rheum Dis. 2017; 76( 10):647-53.
  9. Miloslavsky E.M., Stone J.H., Unizony S.H. Challenging mimickers of primary systemic vasculitis. Rheum. Dis. Clin. North Am. 2015;41 (1 ):141 -60.
  10. Brown K.K. Pulmonary vasculitis. Proc. Am. Thorac. Soc. 2006;3:48-57.
  11. Wener M.H. Laboratory Tests for Autoimmune Rheumatologie Disorders. (Ed. 4), Educational Review Manual in Rheumatology (P. 1-42). New York, 2007.
  12. Choi H.K., Lamprecht P., Niles J.L., et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum. 2000;43(1 ):226-31.
  13. Berden A.E., Kallenberg C.G., Savage C.О., et al. Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. Arthritis Rheum. 2009;60(6):1578-587.
  14. Stegeman C.A., Tervaert J.W., Sluiter W.J., et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994.120(1 ):12-7.
  15. Mandl L.A., Solomon D.H., Smith E.L., et al. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis. Arch. Intern. Med. 2002;162:1509-14.
  16. Cordier J.-F., Valeyre D., Guillevin L., et al. Pulmonary Wegener's gran- ulomatosis. A clinical and imaging study of 77 cases. Chest. 1990;97:906-12.
  17. Boomsma M.M., Stegeman C.A., van der Leij M.J., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43(9):2025-33.
  18. Mukhtyar C., Guillevin L., Cid M.C., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 2009;68(3):310-17.
  19. Green R.J., Ruoss SJ., Kraft S.A., et al. Pulmonary capillaritis and alveo- lar hemorrhage. Update on diagnosisandmanagement. Chest. 1997;110(5): 1305-316.
  20. Novikov P.I., Moiseev S.V., Kuznetsova E.I., et al. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatol. Int.2015;35:891-98.
  21. Novikov P., Smitienko I., Bulanov N., Zykova A., Moiseev S. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Ann. Rheum. Dis. 2016.
  22. Ananthakrishnan L., Sharma N., Kanne J.P. Wegener's granulomatosis in the chest: high resolution CT findings. Am. J. Roentgenol. 2009;192:676-82.
  23. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116(6): 488-98.
  24. Hauer H.A., Bajema I.М., van Houwelingen H.C., et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002; 61(1):80-9.
  25. Cohen-Tervaert J.W., van der Woude F.J., Fauci A.S., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch. Intern. Med. 1989; 149:2461-465.
  26. Brown K.K., Stephen K.F., Cool C.D. pulmonary vasculitis. In Murray and Nadel's Textbook of Respiratory Medicine, sixth edition, Published January 1, 2016.
  27. Phillip R., Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin. Exp. Rheumatol. 2008;26(Suppl 51 ):S94-S104.
  28. Moosig F., Bremer J.P., Hellmich B., et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann. Rheum. Dis. 2012.
  29. Guillevin L., Durand-Gasselin B., Cevaiios R., et al. Microscopic poly- angiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421 -30.
  30. Guillevin L., Pagnoux C., Seror R., et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1).19-27.
  31. Mukhtyar C., Lee R., Brown D., et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann. Rheum. Dis. 2009;68(12):1827-832.
  32. Langford C.A., Talar-Williams C., Sneller M.C. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43(8):1836-840.
  33. Faurschou M., Westman K., Rasmussen N., et al: Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64( 10):3472-477.
  34. Silva F., Specks U., Kalra S., et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement - a prospective, open-label pilot trial. Clin. J. Am. Soc. Nephrol. 2010;5(3):445-53.
  35. Fauci A.S., Haynes B.F, Katz P., Wolff S.M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. 1983; 98(1 ):76-85.
  36. de Groot K, Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 2009;150(10):670-80.
  37. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cycbphospha- mide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363(3):221 -32.
  38. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophos- phamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010;363(3):211-20.
  39. Guillevin L., Lhote F., Cohen P., et al. Corticosteroids plus pulse cyclo- phosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995; 38(11):1638-45.
  40. Gaskin G., Pusey C. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther. Apher. 2001; 5(3): 176-81.
  41. Frasca G.M., Soverini M.L., Falaschini A., et al. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Therap. Apher Dial. 2003; 7(6):540-46.
  42. Schmitt W.H., Hagen E.G., Neumann S., et al. Treatment of refractory Wegeners granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004; 65(4) :1440-448.
  43. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003;349(1 У.36-44.
  44. Hiemstra T.F., Walsh M., Mahr A., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381 -388.
  45. Ohtake T., Kobayashi S., Honjou Y., et al: Generalized Wegener's gran- ulomatosis responding to sulfamethoxazole-trimethoprim mono- therapy. Intern. Med. 2001; 40(7).666-70.
  46. Gayraud M., Guillevin L., le Тоитеlіп P., et al. Long-term follow up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001. 44(3):666-75.
  47. Gordon М., Luqmani R.A., Adu D., et al. Relapses in patients with a systemic vasculitis. Q J. Med. 1993;86(12):779-89.
  48. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Arthritis Rheum. 2000. 43(5):1021-32.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies